Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $767000.0.

  • TScan Therapeutics' Depreciation & Amortization (CF) fell 2531.65% to $767000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 3897.8%. This contributed to the annual value of $4.1 million for FY2024, which is 2407.41% down from last year.
  • TScan Therapeutics' Depreciation & Amortization (CF) amounted to $767000.0 in Q3 2025, which was down 2531.65% from $698000.0 recorded in Q2 2025.
  • Over the past 5 years, TScan Therapeutics' Depreciation & Amortization (CF) peaked at $1.5 million during Q1 2023, and registered a low of $469000.0 during Q1 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $1.1 million, with a median of $1.1 million in 2021.
  • In the last 5 years, TScan Therapeutics' Depreciation & Amortization (CF) skyrocketed by 20520.23% in 2021 and then crashed by 4593.3% in 2025.
  • TScan Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $1.1 million in 2021, then increased by 29.95% to $1.5 million in 2022, then decreased by 13.75% to $1.3 million in 2023, then tumbled by 44.45% to $711000.0 in 2024, then increased by 7.88% to $767000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $767000.0 for Q3 2025, versus $698000.0 for Q2 2025 and $678000.0 for Q1 2025.